Well Referenced

Tag: appetite suppression

Oxytocin’s Inhibitory Effect on Food Intake is Stronger in Obese than Normal-Weight Men

This 2016 double-blind, placebo-controlled study investigated the effects of intranasal oxytocin (24 IU) on food intake and metabolic parameters in 18 obese and 20 normal-weight men. Oxytocin significantly reduced hunger-driven food intake in the fasted state among obese participants but not in normal-weight individuals. Additionally, oxytocin decreased snack consumption in

Read More »
June 26, 2025 No Comments

Lorcaserin: A Review of its Use in Chronic Weight Management

This 2013 review evaluates lorcaserin, a selective 5-HT₂C receptor agonist, for chronic weight management in obese and overweight adults. Clinical trials demonstrated that lorcaserin, as an adjunct to diet and exercise, led to significant weight loss compared to placebo. After 12 months, a higher proportion of lorcaserin-treated patients achieved ≥5%

Read More »
June 26, 2025 No Comments

Naltrexone Sustained-Release/Bupropion Sustained-Release for the Management of Obesity: Review of the Data to Date

This 2014 systematic review evaluates the efficacy and safety of the naltrexone sustained-release/bupropion sustained-release (NB SR) combination, marketed as Contrave®, for obesity management. Clinical trials indicate a placebo-subtracted weight loss of approximately 4.5%, comparable to other anti-obesity medications. The combination targets central nervous system pathways to reduce appetite and food

Read More »
June 26, 2025 No Comments

A New Horizon: Oxytocin as a Novel Therapeutic Option for Obesity and Diabetes

This 2013 review explores oxytocin (OXT) as a potential therapeutic agent for obesity and diabetes. Traditionally recognized for its role in reproduction, OXT has been found to influence metabolic regulation by acting on the hypothalamus to suppress appetite and increase energy expenditure. Animal studies demonstrate that OXT administration leads to

Read More »
June 26, 2025 No Comments

Chronic Oxytocin Administration Inhibits Food Intake, Increases Energy Expenditure, and Produces Weight Loss in Fructose-Fed Obese Rhesus Monkeys

This 2015 study investigated the effects of chronic oxytocin (OT) administration on weight loss in diet-induced obese (DIO) male rhesus monkeys. Over a 4-week period, monkeys received subcutaneous OT injections at escalating doses (0.2 mg/kg for 2 weeks, then 0.4 mg/kg for 2 weeks). Results showed a significant reduction in

Read More »
June 26, 2025 No Comments

New Drug Therapies for the Treatment of Overweight and Obese Patients

This 2013 review discusses pharmacologic options for obesity management, emphasizing the role of medications as adjuncts to lifestyle modifications. At the time, four FDA-approved drugs were available: orlistat, lorcaserin (Belviq), phentermine/topiramate (Qsymia), and naltrexone/bupropion (Contrave). Orlistat functions by inhibiting fat absorption, while the others act centrally to suppress appetite. Clinical

Read More »
June 26, 2025 No Comments

Eating Behavior and Adherence to Dietary Prescriptions in Obese Adult Subjects Treated with 5-Hydroxytryptophan

This double-blind, placebo-controlled clinical trial evaluated the effects of 5-hydroxytryptophan (5-HTP) on eating behavior and dietary adherence in 20 obese adults over two consecutive 6-week periods. Participants received either 900 mg/day of 5-HTP or placebo. During the first period, no dietary restrictions were imposed; in the second, a 5040 kJ/day

Read More »
June 26, 2025 No Comments

Effects of a Natural Extract of (-)-Hydroxycitric Acid (HCA-SX) and a Combination of HCA-SX Plus Niacin-Bound Chromium and Gymnema Sylvestre Extract on Weight Loss

This 8-week randomized, double-blind, placebo-controlled trial evaluated the efficacy of HCA-SX (4667 mg/day) alone and combined with niacin-bound chromium (NBC, 4 mg/day) and Gymnema sylvestre extract (GSE, 400 mg/day) in 60 moderately obese adults (BMI >26 kg/m²). Participants followed a 2000 kcal/day diet and engaged in supervised walking. Both HCA-SX

Read More »
June 26, 2025 No Comments

Effects of Coleus Forskohlii Supplementation on Body Composition and Hematological Profiles in Mildly Overweight Women

This 12-week randomized, double-blind, placebo-controlled study assessed the effects of Coleus forskohlii (CF) supplementation on body composition and hematological profiles in 23 mildly overweight women. Participants received either 250 mg of 10% CF extract twice daily or a placebo. The CF group showed a trend toward mitigating weight gain, with

Read More »
June 26, 2025 No Comments

To Evaluate Efficacy and Safety of Caralluma Fimbriata in Overweight and Obese Patients: A Randomized, Single Blinded, Placebo Control Trial

This 12-week randomized, single-blind, placebo-controlled trial assessed the efficacy and safety of Caralluma fimbriata extract (CFE) in 89 overweight and obese individuals. Participants received either 1 g/day of CFE or a matching placebo. Both groups exhibited numerical reductions in weight, BMI, waist and hip circumference, and waist-hip ratio; however, these

Read More »
June 26, 2025 No Comments